Pre-therapeutic evaluation and practical management of cardiovascular and renal toxicities in patients with metastatic radioiodine-refractory thyroid cancer treated with lenvatinib

MLA

Wassermann, Johanna, et al. “Pre-Therapeutic Evaluation and Practical Management of Cardiovascular and Renal Toxicities in Patients with Metastatic Radioiodine-Refractory Thyroid Cancer Treated with Lenvatinib.” Expert Opinion on Drug Safety, vol. 21, no. 11, Nov. 2022, pp. 1401–10. EBSCOhost, https://doi.org/10.1080/14740338.2022.2153115.

APA

Wassermann, J., Bagnis, C. I., Leenhardt, L., Ederhy, S., & Buffet, C. (2022). Pre-therapeutic evaluation and practical management of cardiovascular and renal toxicities in patients with metastatic radioiodine-refractory thyroid cancer treated with lenvatinib. Expert Opinion on Drug Safety, 21(11), 1401–1410. https://doi.org/10.1080/14740338.2022.2153115

Chicago

Wassermann, Johanna, Corinne Isnard Bagnis, Laurence Leenhardt, Stéphane Ederhy, and Camille Buffet. 2022. “Pre-Therapeutic Evaluation and Practical Management of Cardiovascular and Renal Toxicities in Patients with Metastatic Radioiodine-Refractory Thyroid Cancer Treated with Lenvatinib.” Expert Opinion on Drug Safety 21 (11): 1401–10. doi:10.1080/14740338.2022.2153115.